Atacand HCT

Atacand HCT is a brand name of candesartan/hydrochlorothiazide, approved by the FDA in the following formulation(s):

ATACAND HCT (candesartan cilexetil; hydrochlorothiazide - tablet; oral)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: September 5, 2000
  
  Strength(s): 16MG;12.5MG, 32MG;12.5MG
  


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: May 16, 2008
  
  Strength(s): 32MG;25MG ^[RLD]

Has a generic version of Atacand HCT been approved?

No. There is currently no therapeutically equivalent version of Atacand HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atacand HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-c arboxylate and compositions and methods of pharmaceutical use thereof
  Patent 5,196,444
  Issued: March 23, 1993
  Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
  Assignee(s): Takeda Chemical Industries, Ltd.
  1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-car boxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
  
  Patent expiration dates:
  
  
  • June 4, 2012
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • December 4, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions for oral use and method of preparing them
  Patent 5,534,534
  Issued: July 9, 1996
  Inventor(s): Makino; Tadashi & Mizukami; Yashio & Kikuta; Jun-ichi
  Assignee(s): Takeda Chemical Industries, Ltd.
  A pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) having antagonistic action to angiotensin II ##STR1## (wherein the ring W is an optionally substituted N-containing heterocyclic residue; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2) and an oily substance having a lower melting point, and a method for preparing a pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) and an oily substance having a lower melting point, which comprises admixing the compound of the formula (I) with an oily substance having a lower melting point and then subjecting the mixture to molding.
  
  Patent expiration dates:
  
  
  • July 9, 2013
    
    ✓ 
    Drug product
  
  
  
  • January 9, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Benzimidazole derivatives and use thereof
  Patent 5,705,517
  Issued: January 6, 1998
  Inventor(s): Naka; Takehiko & Nishikawa; Kohei
  Assignee(s): Takeda Chemical Industries, Ltd.
  Benzimidazole derivatives of the formula (I): ##STR1## wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R' group; R' is hydrogen or an optionally substituted hydrocarbon residue; R.sup.2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R' is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is --O--, --S(O).sub.m -- or --N(R.sup.4)-- wherein m is an integer of 0, 1 or 2 and R.sup.4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
  
  Patent expiration dates:
  
  
  • October 18, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical composition for angiotensin II-mediated diseases
  Patent 5,721,263
  Issued: February 24, 1998
  Inventor(s): Inada; Yoshiyuki & Kubo; Keiji
  Assignee(s): Takeda Chemical Industries, Ltd.
  This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m-- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
  
  Patent expiration dates:
  
  
  • February 24, 2015
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition for angiotensin II-mediated diseases
  Patent 5,958,961
  Issued: September 28, 1999
  Inventor(s): Inada; Yoshiyuki & Kubo; Keiji
  Assignee(s): Takeda Chemical Industries, Ltd.
  This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
  
  Patent expiration dates:
  
  
  • June 6, 2014
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  



• 
  Benzimidazole derivatives, their production and use
  Patent 7,538,133
  Issued: May 26, 2009
  Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
  Assignee(s): Takeda Pharmaceutical Company Limited
  Benzimidazole derivatives of the formula (I): wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; R2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O)m— or —N(R4)— wherein m is an integer of 0, 1 or 2 and R4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
  
  Patent expiration dates:
  
  
  • October 18, 2011
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Atacand HCT Consumer Information (Wolters Kluwer)
• Atacand HCT Consumer Information (Cerner Multum)
• Atacand HCT Advanced Consumer Information (Micromedex)
• Candesartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and candesartan Consumer Information (Cerner Multum)
• Atacand Oral Advanced Consumer Information (Micromedex)
• Candesartan and hydrochlorothiazide Advanced Consumer Information (Micromedex)